Stepwise increase of fidaxomicin in an engineered heterologous host Streptomyces albus through multi-level metabolic engineering

Huang Xie,Yi-Ting Su,Qing-Ting Bu,Yue-Ping Li,Qing-Wei Zhao,Yi-Ling Du,Yong-Quan Li
DOI: https://doi.org/10.1016/j.synbio.2024.06.004
IF: 4.692
2024-06-19
Synthetic and Systems Biotechnology
Abstract:The anti- Clostridium difficile infection (CDI) drug fidaxomicin is a natural polyketide metabolite mainly produced by Micromonosporaceae , such as Actinoplanes deccanensis , Dactylosporangium aurantiacum , and Micromonospora echinospora . In the present study, we employed a stepwise strategy by combining heterologous expression, chassis construction, promoter engineering, activator and transporters overexpression, and optimization of fermentation media for high-level production of fidaxomicin. The maximum yield of 384 mg/L fidaxomicin was achieved with engineered Streptomyces albus D7-VHb in 5L-tank bioreactor, and it was approximately 15-fold higher than the native strain Actinoplanes deccanensis YP-1 with higher strain stability and growth rate. This study developed an enhanced chassis strain, and for the first time, achieved the heterologous synthesis of fidaxomicin through a combinatorial metabolic engineering strategy.
biotechnology & applied microbiology
What problem does this paper attempt to address?